This study focuses on people with severe asthma, a condition where breathing becomes difficult due to inflammation and narrowing of the airways. The study will test a medication called Verekitug (also known as UPB-101), which is given as an injection under the skin. This medicine is a type of monoclonal antibody, which is a protein designed to target specific substances in the body that contribute to asthma symptoms.
The purpose of this research is to evaluate the safety and effectiveness of long-term treatment with Verekitug in adults who have previously participated in another study called VALIANT. During the study, participants will receive either Verekitug or a placebo as an injection under the skin for approximately 60 weeks. The study will monitor how well participants’ asthma is controlled and how their breathing functions over time.
Throughout the study, participants will have regular check-ups that include breathing tests, blood samples, and questionnaires about their asthma symptoms. The study will track how often participants experience asthma flare-ups that require treatment with steroids. Blood samples will be collected to measure the amount of medicine in the body and to check for the body’s immune response to the treatment.
Bulgaria 
Czechia 
Germany 
Italy 
Poland 
Spain